Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Терапия острых болевых синдромов в неврологии
Терапия острых болевых синдромов в неврологии
О.В.Котова. Терапия острых болевых синдромов в неврологии. Consilium Medicum. Неврология (Прил.). 2013; 2: 20-23.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Насонова В.А., Багирова Г.Г. Боль в нижней части спины у подростков. Лечащий врач. 2005; 11: 40–2.
2. Carey TS, Garrett JM, Jackman A et al. Recurrence and care seeking after acute back pain: results of a long-term follow-up study. North Carolina Back Pain Project. Med Care 1999; 37: 157–64.
3. Martin BI, Deyo RA, Mirza SK et al. Expenditures and health status among adults with back and neck problems. JAMA 2008; 299 (6): 656–64.
4. Pengel LH, Herbert RD, Maher CG et al. Acute low back pain: systematic review of its prognosis. BMJ 2003; 9: 327 (7410): 323.
5. Van Tulder M, Becker A, Bekkering T et al. European guidelines for the management of acute nonspecific low back pain in primary care. Eur Spine J 2006; 15 (2): 169–91.
6. Schiottz-Christensen B, Nielsen GL, Hansen VK et al. Long-term prognosis of acute low back pain in patients seen in general practice: a 1-year prospective follow-up study. Fam Pract 1999; 16: 223–32.
7. Hestbaek L, Leboeuf-Yde C, Manniche C. Lowbackpain: whatisthelong-termcourse? A review of studies of general patient populations. Eur Spine J 2003; 12: 149–65.
8. Подчуфарова Е.В., Яхно Н.Н. Боли в спине и конечностях. В кн.: Болезни нервной системы. Руководство для врачей. Под ред. Н.Н.Яхно. М., 2005; 2: 306–31.
9. Burton AK, Balague F, Carbon Metal. forthe COSTB 13 working group one uropean guidelines for prevention in lowback pain. How to prevent low back pain. Best Pract Res Clin Rheumatol 2005; 19: 541–55.
10. Waddell G, Feder G, Lewis M. Systematic reviews of bed rest and advice to stay active for acute low back pain. Br J Gen Pract 1997; 47: 647–52.
11. Bair M, Robinson R, Katon W et al. Depression and pain comorbidity: a literature review. Arch Intern Med 2003; 163: 2433–45.
12. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspiei-like drugs. Nature 1971; 231: 235–9.
13. Dong L, Smith J, Winkelstein B. Ketorolac reduces spinal astrocytic activation and PAR1 expression associated with attenuation of pain following facet joint injury. J. Neurotrauma 2012. [Epub ahead of print].
14. Mazzocca A, McCarthy M, Intravia J et al. An In Vitro Evaluation of the Anti-Inflammatory Effects of Platelet-Rich Plasma, Ketorolac, and Methylprednisolone. Arthroscopy. 2013. pii: S0749–8063(12)01896–8. doi: 10.1016/j.arthro.2012.12.005.
15. Larkin GL, Peacock WF et al. Efficacy of ketorolac tromethamine versus meperidine in the ED treatment of acute renal colic.Am J Emerg Med 1999; 17 (1): 6–10.
16. Pérez-Urizar J, Granados-Soto V et al. Analgesic efficacy and bioavailability of ketorolac in postoperative pain: a probability analysis. Arch Med Res 2000; 31 (2): 191–6.
17. Henschke N, Maher CG, Refshauge KM et al. Prognosis in patients with recent onset low back pain in Australian primary care: inception cohort study. BMJ 2008; 337: a171.
18. Veenema KR, Leahey N, Schneider S. Ketorolac versus meperidine: ED treatment of severe musculoskeletal low back pain. Am J Emerg Med 2000; 18 (4): 404–7.
19. Innes GD, Croskerry P. Ketorolac versus acetaminophen-codeine in the emergency department treatment of acute low back pain. J Emerg Med 1998; 16 (4): 549–56.
20. Верткин А.Л., Прохорович Е.А., Горулева Е.А. и др. Эффективность и безопасность применения Кеторола для купирования болевого синдрома на догоспитальном этапе. Неотложная терапия. 2004; 1–2; 16–17: 12–17.
21. Шостак Н.А., Правдюк Н.Г., Аксенова А.В. и др. Возможности оптимизации анальгетической и противовоспалительной терапии у больных с острым болевым синдромом в спине. РМЖ. 2006; 14 (8): 610–5.
22. Bjarnason I. Gastrointestinal safety of NSAID sandover-the-counteranalgesics. Int J Clin Pract 2013; 178 (Suppl.): 37–42.
23. Gillis JC, Brogden RN. Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 1997; 53 (1): 139–88.
24. Quan DJ, Kayser SR. Ketorolac induced acute renal failure following a single dose. J Toxicol Clin Toxicol 1994; 32 (3): 305–9.
25. Freedland SJ, Blanco-Yarosh M et al. Effect of ketorolac on renal function after donor nephrectomy. Urology 2002; 59 (6): 826–30.
26. Feldman HI, Kinman JL, Berlin JA et al. Parenteral ketorolac: the risk for acute renal failure. Ann Intern Med 1997; 126 (3): 193–9.
27. Lee A, Cooper MG, Craig JC et al. The effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on postoperative renal function: a meta-analysis. Anaesth Intensive Care 1999; 27 (6): 574–80.
2. Carey TS, Garrett JM, Jackman A et al. Recurrence and care seeking after acute back pain: results of a long-term follow-up study. North Carolina Back Pain Project. Med Care 1999; 37: 157–64.
3. Martin BI, Deyo RA, Mirza SK et al. Expenditures and health status among adults with back and neck problems. JAMA 2008; 299 (6): 656–64.
4. Pengel LH, Herbert RD, Maher CG et al. Acute low back pain: systematic review of its prognosis. BMJ 2003; 9: 327 (7410): 323.
5. Van Tulder M, Becker A, Bekkering T et al. European guidelines for the management of acute nonspecific low back pain in primary care. Eur Spine J 2006; 15 (2): 169–91.
6. Schiottz-Christensen B, Nielsen GL, Hansen VK et al. Long-term prognosis of acute low back pain in patients seen in general practice: a 1-year prospective follow-up study. Fam Pract 1999; 16: 223–32.
7. Hestbaek L, Leboeuf-Yde C, Manniche C. Lowbackpain: whatisthelong-termcourse? A review of studies of general patient populations. Eur Spine J 2003; 12: 149–65.
8. Подчуфарова Е.В., Яхно Н.Н. Боли в спине и конечностях. В кн.: Болезни нервной системы. Руководство для врачей. Под ред. Н.Н.Яхно. М., 2005; 2: 306–31.
9. Burton AK, Balague F, Carbon Metal. forthe COSTB 13 working group one uropean guidelines for prevention in lowback pain. How to prevent low back pain. Best Pract Res Clin Rheumatol 2005; 19: 541–55.
10. Waddell G, Feder G, Lewis M. Systematic reviews of bed rest and advice to stay active for acute low back pain. Br J Gen Pract 1997; 47: 647–52.
11. Bair M, Robinson R, Katon W et al. Depression and pain comorbidity: a literature review. Arch Intern Med 2003; 163: 2433–45.
12. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspiei-like drugs. Nature 1971; 231: 235–9.
13. Dong L, Smith J, Winkelstein B. Ketorolac reduces spinal astrocytic activation and PAR1 expression associated with attenuation of pain following facet joint injury. J. Neurotrauma 2012. [Epub ahead of print].
14. Mazzocca A, McCarthy M, Intravia J et al. An In Vitro Evaluation of the Anti-Inflammatory Effects of Platelet-Rich Plasma, Ketorolac, and Methylprednisolone. Arthroscopy. 2013. pii: S0749–8063(12)01896–8. doi: 10.1016/j.arthro.2012.12.005.
15. Larkin GL, Peacock WF et al. Efficacy of ketorolac tromethamine versus meperidine in the ED treatment of acute renal colic.Am J Emerg Med 1999; 17 (1): 6–10.
16. Pérez-Urizar J, Granados-Soto V et al. Analgesic efficacy and bioavailability of ketorolac in postoperative pain: a probability analysis. Arch Med Res 2000; 31 (2): 191–6.
17. Henschke N, Maher CG, Refshauge KM et al. Prognosis in patients with recent onset low back pain in Australian primary care: inception cohort study. BMJ 2008; 337: a171.
18. Veenema KR, Leahey N, Schneider S. Ketorolac versus meperidine: ED treatment of severe musculoskeletal low back pain. Am J Emerg Med 2000; 18 (4): 404–7.
19. Innes GD, Croskerry P. Ketorolac versus acetaminophen-codeine in the emergency department treatment of acute low back pain. J Emerg Med 1998; 16 (4): 549–56.
20. Верткин А.Л., Прохорович Е.А., Горулева Е.А. и др. Эффективность и безопасность применения Кеторола для купирования болевого синдрома на догоспитальном этапе. Неотложная терапия. 2004; 1–2; 16–17: 12–17.
21. Шостак Н.А., Правдюк Н.Г., Аксенова А.В. и др. Возможности оптимизации анальгетической и противовоспалительной терапии у больных с острым болевым синдромом в спине. РМЖ. 2006; 14 (8): 610–5.
22. Bjarnason I. Gastrointestinal safety of NSAID sandover-the-counteranalgesics. Int J Clin Pract 2013; 178 (Suppl.): 37–42.
23. Gillis JC, Brogden RN. Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 1997; 53 (1): 139–88.
24. Quan DJ, Kayser SR. Ketorolac induced acute renal failure following a single dose. J Toxicol Clin Toxicol 1994; 32 (3): 305–9.
25. Freedland SJ, Blanco-Yarosh M et al. Effect of ketorolac on renal function after donor nephrectomy. Urology 2002; 59 (6): 826–30.
26. Feldman HI, Kinman JL, Berlin JA et al. Parenteral ketorolac: the risk for acute renal failure. Ann Intern Med 1997; 126 (3): 193–9.
27. Lee A, Cooper MG, Craig JC et al. The effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on postoperative renal function: a meta-analysis. Anaesth Intensive Care 1999; 27 (6): 574–80.
Авторы
О.В.Котова
ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России
ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.